YES, WE CAN

Our goal is simple, to improve lives by increasing access to medicines around the world.

We deliver solutions for organizations in the global healthcare network, removing barriers and implementing programs so they can:

  • Provide access to medicines for patients in need
  • Demonstrate the value of new medications
  • Enable better health

YES, WE WILL

Our commitment is unwavering.

We relentlessly pursue and deliver the best solutions to enable access, no matter how challenging the situation. We are resourceful and creative and always going the extra mile.

YES, WE DID

The Challenge:

Reduce the risk of infection in leukemia patients.

LEUKINE®, approved by the US FDA in 1991, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection.

In 2018, Partner Therapeutics, Inc. (PTx) acquired the global rights to develop, manufacture, and commercialize Leukine ® (sargramostim) from Sanofi. As a small company, Ptx did not have the internal resources to handle international requests for the drug and didn’t know how they could successfully support patients outside the US, in full regulatory compliance, even though the product was not registered in other geographies.

 

Read More

YES, WE DID

The Challenge:

Provide free cancer treatment to patients around the world

The Max Foundation is a global non-profit organization focused on increasing the access to treatment, care and support for people living with cancer around the world. In 2017 the Foundation sought to put in place The Max Access Solutions program, a patient-centric care model for delivering free cancer treatment to those in need. The Foundation wanted to be able to offer its patients targeted treatment using a portfolio of oncology medicines from multiple pharmaceutical companies. They sought a partner to handle the distribution, quality assurance and regulatory activities to safely and securely store, handle and deliver the medicines to their patients. After evaluating options for a partner to manage the distribution, Tanner was selected.

Read More

YES, WE DID

The Challenge:

Uninterrupted distribution to patients in Latin America

A major pharmaceutical company divested a mature pipeline asset to a medium size pharma company that did not have a presence in Latin America, but wanted to continue distribution of the product.

Read More

YES, WE DID

The Challenge:

Assuring continuity during a global pandemic

A leading clinical-stage biotechnology company required packs of a comparator to conduct a Phase III trial for their leading asset. They required the stock in a single lot, and because of the ongoing COVID-19 pandemic, wanted stock with a long shelf life and additional assurances regarding the supply chain to minimize lead times and the chance of unexpected manufacturer disruptions.

Read More

TESTIMONIAL

Tanner Pharma Group is truly an example of what it means to put humanity at the center of their business. This was not just words on a page or some empty mission statement, it’s compassion in action!

They are a prime example on how Pharma should be running their business and focusing their motivation.

Joshua Frase Foundation

PROVIDING ACCESS TO

120+

countries with the help of our non-profit collaborators:

PROVIDING ACCESS TO

RECENT NEWS & EVENTS

  1. Again Life Italia Announces Partnership with Tanner Pharma Group

    CHARLOTTE, N.C., May 27, 2021 — Again Life Italia S.r.l. (“ALI”), a pharmaceutical biotechnology company headquartered in Italy, and TannerLAC UK Limited (“TannerLAC”), a wholly owned subsidiary of Tanner Pharma Group and company leader in the Latin American market, announced today the signing of a business partnership agreement for Latin America.  With a presence in…

    Read More
  2. Epimune and Tanner Pharma Group enter into Distribution Partnership for Latin America

    Berlin, 27 January 2021 – Epimune GmbH, a molecular diagnostic company that develops, manufactures and commercializes in-vitro diagnostic tests for immune cell quantification from a drop of blood, announced today that it has entered into a license agreement with TannerLAC UK Limited (“TannerLAC”), a wholly owned subsidiary of Tanner Pharma Group for the i.Mune TBNK in-vitro…

    Read More
  3. Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access to Apealea® (paclitaxel micellar)

    SALT LAKE CITY and CHARLOTTE, N.C., Dec. 1, 2020 /PRNewswire/ — Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, and Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, announced today that they have launched a global…

    Read More

FEATURE

Max Global Experience: Uganda

Tanner Pharma Group is proud to serve as the title sponsor for The Max Foundation’s 2018 “Max Global Experience: Uganda,” an expedition to raise awareness and funds for increased cancer treatment access in Africa.

Read More

Tanner Pharma Group uses cookies on its website. By continuing to access this website you are agreeing to Tanner Pharma Group’s Data Privacy Policy. For more information, click here.